Fact Sheet

About thyssenkrupp nucera

thyssenkrupp nucera is a leading global provider of electrolysis technologies. With alkaline water electrolysis (AWE), which is used to produce green hydrogen on an industrial scale, the company supports its customers on their way to climate neutrality. By investing in future technologies such as high-temperature electrolysis (SOEC), thyssenkrupp nucera is expanding its product portfolio in the green hydrogen segment and strengthening its leading market position.

The chlor-alkali (CA) business is thyssenkrupp nucera's sustainably profitable core business. About half of its sales come from the high-margin service business across the entire plant life cycle. This ensures recurring revenues and a high degree of planning security.

thyssenkrupp nucera relies on its technological leadership in electrolysis with over 60 years of experience, a global organization with over 1,000 employees, an asset-light business modell, an industry-leading project pipeline and a strong balance sheet to finance future growth. Overall, the company is well positioned to take advantage of the long-term growth opportunities of the green hydrogen market and to grow profitably.

Management & Supervisory Board









Chairman of the Supervisory

Dr. Volkmar Dinstuhl

All members of the

supervisory board



Dr. Werner Ponikwar

CFO

Dr. Stefan Hahn

CFO

Klaus Ohliq

СТО



Technology leader in electrolysis



Green hydrogen as a key factor for decarbonization and climate neutrality



Well positioned to manage current sector challenges



Strong balance sheet to finance future growth



Last updated: 07/01/2025

Analyst coverage

Institution	Rating	Price target (€)	Last update
Berenberg	Hold	11	2/17/2025
Citi	Buy	17	5/7/2025
Deutsche Bank	Buy	12	5/16/2025
Goldman Sachs	Sell	8.60	6/30/2025
Intesa	Sell	8.80	5/16/2025
Kepler Cheuvreux	Buy	14.50	5/19/2025
Metzler	Hold	9.30	12/17/2024
mwb research	Buy	12	5/15/2025
ODDO BHF	Buy	13	12/18/2024
Pekao S.A.	Buy	13	10/28/2024
Redburn	Buy	15.50	1/10/2025
Royal Bank of Canada	Buy	15	4/28/2025
Santander	Sell	10	7/31/2024

Financial calendar


08/13/2025 Publication of Q3/9M Results 2024/2025



12/17/2025 Publication of Annual Report FY 2024/2025

Shareholder structure





IR and media contacts

ir@thyssenkrupp-nucera.com
press@thyssenkrupp-nucera.com
http://www.thyssenkrupp-nucera.com





Last updated: 07/01/2025

Key figures


in mn €	FY 2021/22	FY 2022/23 ¹	FY 2023/24
Order intake	1,340	613	636
thereof gH ₂	970	206	356
thereof CA	370	408	279
Order backlog	~1.5	~1.4	~1.1
Sales	383	661	862
thereof gH2	51	328	524
thereof CA	332	333	338
EBITDA	12	30	-8
EBIT	9	25	-14
Earnings per share (in €)	0.06	0.22	0.09
R&D expenses	16	19	36
Net financial assets ²	275	761	673
CapEx	1	4	13
Employees ² (headcount)	509	675	1,012

¹ The figures for FY 2022/23 have been retrospectively adjusted in accordance with IAS 8.41.

Please find the recent publications <u>here</u>.


You can find an interactive comparison of key figures here.

Outlook FY 2024/25





You can find our latest consensus here.





² As of the reporting date Sept, 30.

Locations & selected projects

